Complement C3 and Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease Patients: A Pilot Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Complement C3 and Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease Patients: A Pilot Study ; volume:45 ; number:1 ; year:2020 ; pages:61-69
Kidney & blood pressure research ; 45, Heft 1 (2020), 61-69
- Urheber
-
Pan, Binbin
Wan, Xin
Ma, Mengqing
Cao, Changchun
- DOI
-
10.1159/000504172
- URN
-
urn:nbn:de:101:1-2020020523123258939172
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pan, Binbin
- Wan, Xin
- Ma, Mengqing
- Cao, Changchun
Ähnliche Objekte (12)
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease
Nonalcoholic fatty liver disease and cardiovascular disease risk
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Artificial intelligence in nonalcoholic fatty liver disease
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease, diet and gut microbiota
Resveratrol inhibits nonalcoholic fatty liver disease in rats
Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease
Nonalcoholic fatty liver disease and cardiovascular disease risk
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Artificial intelligence in nonalcoholic fatty liver disease
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease, diet and gut microbiota
Resveratrol inhibits nonalcoholic fatty liver disease in rats
Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease
Nonalcoholic fatty liver disease and cardiovascular disease risk
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Artificial intelligence in nonalcoholic fatty liver disease
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease, diet and gut microbiota
Resveratrol inhibits nonalcoholic fatty liver disease in rats